Trial Ready
The University of Oxford receives its first batch of AZD1222, a coronavirus vaccine candidate.
Academics at the Jenner Institute at the University of Oxford, UK, have received 4000
doses of AZD1222 (formerly known as ChAdOx1 nCoV-19) for use in a Phase 2/3
trial from Italian contract manufacturer Advent, part of the IRBM Group.
Credit: Advent, IRBM
